Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)-Reference-Cited by-同舟云学术

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)

Published:2020-03-24 Issue:2 Volume:21 Page:275-284
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Schlessinger Joel,Shepard Julie S.,Gower Richard,Su John C.^ORCID,Lynde Charles,Cha Amy,Ports William C.,Purohit Vivek,Takiya Liza,Werth John L.,Zang Chuanbo,Vlahos Bonnie,

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-020-00510-6.pdf

Reference23 articles.

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.

2. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int J Clin Pract. 2006;60(8):984–92.

3. Eichenfield LF, Ellis CN, Mancini AJ, Paller AS, Simpson EL. Atopic dermatitis: epidemiology and pathogenesis update. Semin Cutan Med Surg. 2012;31(3 Suppl):S3–5.